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A B S T R A C T
We analyzed Gag-specific CD8+ T-cells in HIV-patients on long-term HAART and in untreated chronically-infected
patients by using iTAg MHC class I tetramers (HLA-A*0201) specific for SLYNTVATL. Gag SLYNTVATL-specific CD8
+
T-cells were detectable in 18 of 26 treated patients (median 5.2 years of HAART) and in 10 of 14 untreated patients. Me-
dian percentage of Gag SLYNTVATL-specific CD8
+ T-cells in treated patients was 0.10 (range 0.00–0.70%). Median number
of Gag SLYNTVATL-specific CD8
+ T-cells per 50,000 CD8+ T-cells was 56.0 cells (range 2.0–344.0 cells) and was not signifi-
cantly different compared with untreated patients (p=0.978). Numbers of Gag SLYNTVATL-specific CD8
+ T-cells were in-
versely correlated with the duration of undetectable plasma viremia (p=0.02, Rho= –0.430). Chronically-infected HIV-
patients on HAART (for up to 7.7 years) maintained a stable subpopulation of Gag SLYNTVATL-specific CD8
+ T-cells. This
finding is relevant for the analysis of treatment-induced immune reconstitution and, possibly, for future therapeutic
strategies in HIV-disease.
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Introduction
Introduction of tetramer technology capable of direct
ex vivo enumeration of antigen-specific cells enabled a
detailed quantitative characterization of HIV-specific
T-cell responses in different stages of infection and/or
disease. Although HIV-specific CD8+ T-cells can be de-
tected in the majority of chronically infected individuals,
they are unable to eradicate the virus and/or maintain a
successful control of virus replication1. Limited efficacy
of HIV-specific CD8+ T-cell immunity can be, at least in
part, attributed to loss of CD4+ T-cell help, impaired an-
tigen presentation and signal transduction, aberrations
in surface phenotype and intracellular cytokine synthe-
sis, viral evasion etc2–5.
Nevertheless, antigen-specific CD8+ T-cells appear to
be critical for the partial containment of HIV-1/SIV repli-
cation at the chronic stage of infection4,6. Interestingly,
several longitudinal and cross-sectional studies showed
that HIV-specific T-cells impose a selective pressure on
HIV-1 that results in viral evolution during chronic infec-
tion7–10. Moreover, it is possible that long-term efficient
anti-HIV treatment will require augmentation of virus-
specific T-cell responses as well.
Literature data regarding the impact of HAART on
HIV-specific CD8+ T-cell immunity at different stages of
infection and/or disease are variable. Several studies
showed HAART-induced decline in HIV-specific cellular
immune responses in asymptomatic as well as advanced
patients but other reports contradicted these find-
ings11–17. For example, Appay et al. (2002) showed the
presence of CD4+ and CD8+ HIV-specific responses in pa-
tients with 3–4 years of virologically and clinically suc-
cessful HAART16. Similarly, Rinaldo et al. detected a sta-
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ble, residual population of potentially immunocompetent
HIV-1-specific T-cells in advanced patients on long-term
HAART15. Moreover, examples of de novo appearance of
HIV-specific CD8+ T-cells in patients with 6 months of
successful HAART have been described17.
The majority of the abovementioned studies investi-
gated the frequency of HIV-specific T-cell responses in
patients with less than 4 years of HAART. The aim of our
study was to investigate the frequency and absolute
counts of Gag SLYNTVATL-specific CD8
+ T-cells in symp-
tomatic HIV-patients who have been treated for long pe-
riods of time (median 5.2 years) and compare it with un-
treated chronically-infected patients. We also compared
HIV-specific immunity in patients with and without de-
tectable viremia during follow-up. In this study we fo-
cused on CD8+ T-cell responses to Gag p17 of HIV-1.
Materials and Methods
Study design and patients
This prospective, cross-sectional study was done at
the University Hospital for infectious diseases »Dr. Fran
Mihaljevi}«, Zagreb, Croatia between the February and
May 2005.
Sixtyeight HIV-infected patients were screened to ob-
tain HLA-A2-positive group. Flow cytometric expression
of HLA-A2 in the patients was determined by using
anti-human HLA-A2 monoclonal antibody (Proimmune,
Oxford, UK). A group of 40 patients (median age 43.1
years, range from 22.6–67.1 years) were selected for the
study. The patients were divided into two groups: un-
treated HIV-infected individuals (n=14) and patients re-
ceiving long-term HAART (n=26). Twelve of 26 HAART-
treated patients had detectable viremia during follow-up.
A total of 4 treated HIV-patients experienced one viro-
logical failure. Four HLA-A*0201-positive HIV-negative
individuals (n=4) and three HLA-A*0201-negative HIV-
positive patients were also enrolled as controls for the
specificity of tetramer assay.
Peripheral blood samples for immunological (flow cy-
tometry) and plasma samples for virological (quantita-
tive RT-PCR for HIV-1 RNA) analysis were collected as a
part of routine diagnostics.
Informed consent was obtained from all patients and
controls. The study was approved by the Ethics commit-
tee of the University Hospital for Infectious Diseases.
Viral load
The quantification of HIV-1 RNA in the plasma of
HIV-1-infected persons was performed by using Amplicor
HIV-1 monitor Test, version 1.5 (Roche Diagnostic Sys-
tems, Inc., Branchburg, New Jersey, USA) with lower
limit of detection of 50 (ultrasensitive method) copies of
HIV-1 RNA/ml.
Flow cytometry
Percentages of Gag-specific CD8+ T-cells in the pe-
ripheral blood were determined by using phycoerythrin
(PE)-labeled iTAgTM HLA class I tetramers (A*0201) spe-
cific for Gag p17 SLYNTVATL peptide, amino acid
residues 77-85 (Beckman Coulter Immunomics Opera-
tions, USA). Additionally, we used conjugated murine
anti-human monoclonal antibodies (mAb) specific for
CD3 (FITC) and CD8 (RPE-Cy5) (Dako Cytomation A/S,
Glostrup, Denmark).
Peripheral blood cells were first stained with HLA-
tetramers for 15 min. in the dark and then for additional
10 min. with anti-CD3 and anti-CD8 mAbs, at room tem-
perature. After incubation, cells were prepared for analy-
sis by using whole blood non-wash ImmunoPrep Reagent
System on Coulter TQ-prep (Beckman Coulter, Inc., Ful-
lerton, CA, USA). For each sample, we collected 50,000
CD3+CD8+ events and analysed for tetramer expression
on Cytomics FC500 flow cytometer via CXP 2.0 software
(Beckman Coulter, Inc., Fullerton, CA, USA). Absolute
counts of Gag-specific CD8+ T-cells per microliter of pe-
ripheral blood as well as per 50,000 CD8+ T-cells were de-
termined by using Flow-Count Fluorospheres quantifica-
tion reagent (Beckman Coulter, Inc., Fullerton, CA, USA).
Figures 1b and 1c show representative dot plots of
Gag77–85 tetramer staining in HLA-A
*0201-positive HIV-
positive patients. As negative controls we analysed HLA-
A*0201-negative HIV-positive patients (n=4) and HLA-
A*0201-positive HIV-negative healthy persons (n=3).
Percentages of gag-specific CD8+ T-cells in both control
groups were lower than 00.001%.
Percentages of T-cell, CD4+ and CD8+ T-cells, B-cells
and NK-cells in the peripheral blood of HIV-infected pa-
tients were determined by using a four-colour flow cyto-
metry panel CYTO-STAT tetra CHROME (CD45-FITC/
CD4-RD1/CD8-ECD/CD3-PC5 and CD45-FITC/CD56-
RD1/CD19-ECD/CD3-PC5) (Beckman Coulter, Inc., Ful-
lerton, CA, USA) as recommended (CDC). Similarly to
tetramer staining, the preparation of samples for CD4+
T-cell quantification was performed automatically on
Coulter TQ-prep and analysed on Cytomics FC500 cy-
tometer (Beckman Coulter, Inc., Fullerton, CA, USA).
Absolute counts of CD4+ T-cells were also determined di-
rectly on the cytometer by using Flow-Count Fluoro-
spheres (Beckman Coulter, Inc., Fullerton, CA, USA).
Statistical analysis
The Wilcoxon Two-sample test was used for compari-
son of T-cell subpopulations in different patient groups.
The correlation between variables was evaluated with
the Spearman Rank test. Statistical analysis was per-
formed with SAS software version 8.2. (SAS Institute,
Cary, North Carolina, USA).
Results
Patients
Demographic, virological, immunological and clinical
data on untreated HIV-infected patients and patients on
long-term HAART are summarized in Table 1.
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Duration of HAART in 26 selected patients ranged be-
tween 0.3 and 7.7 years (median 5.2 years). Median
pre-treatment CD4+ T-cell count in treated patients was
127 cells/µL (range 1–407 cells/µL). Median pre-treat-
ment percentages of CD4+ and CD8+ T-cells were 8.95%
and 54.1%, respectively. At the time of tetramer analysis,
median CD4+ T-cell count in treated HIV-patients was
396 cells/µL (range 117–965 cells/µL). Median percent-
ages of CD4+ and CD8+ T-cells at the time of tetramer
staining were 22.8% (range 10.6–44.4%) and 46.1%
(22.2–70.4%), respectively. Median lowest recorded CD4+
T-cell count in treated patients was 49 cells/µL. Median
lowest recorded CD4+ T-cell percentage was 7.0%.
Median plasma viremia in untreated patients (n=14)
at the time of tetramer staining was 4.78 log10 copies of
HIV-1 RNA/ml of plasma. Median absolute count of CD4+
T-cells in untreated patients was 256 cells/µL (range
31–525 cells/µL). Median percentages of CD4+ and CD8+
T-cells in untreated patients at the time of HIV-specific
immunity analysis were 20.5% (range 1.6–31.0%) and
53.9% (range 43.1–77.1%), respectively. Median lowest
recorded CD4+ T-cell count in untreated patients was
200 cells/µL. Median lowest recorded CD4+ T-cell per-
centage was 22.0%.
Cellular immune responses to HIV-1 Gag
Ex vivo tetramer staining of CD8+ T-cells was used to
monitor CD8+ T cell responses specific for HLA-A+0201-
restricted HIV-1 gag antigenic peptide SLYNTVATL in
patients on long term successful HAART as well as in un-
treated HIV-infected patients (Figures 1a, 1b and 1c). In
addition to the percentage of Gag SLYNTVATL-specific CD8
+
T-cells, we determined absolute counts of tetramer-posi-
tive cells per µL of the peripheral blood (by using com-
mercially available absolute counting reagent) and per
50,000 CD8+ T-cells. Gag SLYNTVATL-specific CD8
+ T-cells
were detected in 18 of 26 treated patients and in 10 of 14
untreated patients.
Median percentage of Gag SLYNTVATL-specific CD8
+
T-cells in patients on long-term HAART was 0.10 (range
0.00–0.70%) (Table 2). Median number of Gag SLYNTVATL-
specific CD8+ T-cells per µL of the peripheral blood in
treated patients was 1 cells/µl (range 0–6 cells/µL) and,
when expressed per 50,000 CD8+ T-cells, it was 56 cells
(range 2–344 cells).
In untreated patients, median percentage of Gag SLYNT
VATL-specific CD8
+ T-cells was 0.10% (range 0.00–1.10%)
(Table 2). Median number of Gag SLYNTVATL-specific CD8
+
T-cells per µL of the peripheral blood in treated patients
was 1 cells/µl (range 0–9 cells/µl) and, when expressed
per 50,000 CD8+ T-cells, it was 61 cells (range 10–573
cells).
Percentages, number per µL and per 50,000 CD8+
T-cells of Gag SLYNTVATL-specific CD8
+ T-cells in treated
and untreated HIV-pateints were not significantly differ-
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Fig. 1. a) Negative controls (representative plot of tetramer stain-
ing of human immunodeficiency virus type-1-infected HLA-A2-
negative patient). b) Gag SLYNTVATL-specific CD8
+ T-cells in an
untreated HIV-1 infected patient. c) Gag SLYNTVATL-specific
CD8+ T-cells in an HIV-1 infected patient after 7 years of
antiretroviral therapy.
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ent (p=0.202, p=0.579, p=0.533, respectively). Percent-
ages, number per µL and per 50,000 CD8+ T-cells of Gag
SLYNTVATL-specific CD8
+ T-cells in treated patients with or
without detectable viremia during follow-up were not
significantly different (p=0.778, p=0.198, p=0.978, re-
spectively).
Gag-specific T-cell immunity and viremia
Numbers of Gag SLYNTVATL-specific CD8
+ T-cells were
inversely correlated with the duration of HAART-induced
undetectable plasma viremia (p=0.02, Rho= –0.430). Addi-
tionally, numbers of tetramer-positive cells positively
correlated with a total number of CD8+ T-cells (Rho=
0.520, p=0.007).
There was no correlation between pre-treatment plasma
viremia and percentage of tetramer-positive cells (Rh0=
–0.063, p=0.767), number of tetramer-positive cells per
µL of blood (Rho=0.209, p=0.326) and number of tetra-
mer-positive cells per 50,000 CD8+ T-cells (Rho=–0.029,
p=0.890) in treated patients.
In untreated HIV-infected persons, there was no corre-
lation between plasma viremia at the time of analysis and
percentage of tetramer-positive cells (Rh0=–0.059, p=
0.841), number of tetramer-positive cells per µL of blood
(Rho=–0.036, p=0.902) and number of tetramer- positive
cells per 50,000 CD8+ T-cells (Rho=–0.235, p=0.418).
Discussion
Tetramer-based ex vivo analysis is a highly sensitive
tool for the enumeration of antigen-specific cells without
in vitro manipulation. This technique has proven to be a
useful tool in monitoring vaccine and immunotherapy
trials as well as in other types of basic and clinical re-
search where a quantitative characterization of anti-
gen-specific T-cell responses may be of importance. By
using this technology, we demonstrated the presence of
Gag-specific CD8+ T-cell responses in the majority of
HIV-patients who received HAART long periods of time
(up to 7 years). The amplitude of Gag-specific CD8+
T-cell responses (percentage and counts of tetramer-posi-
tive cells) in patients on long-term HAART and un-
treated HIV-infected patients was not significantly dif-
ferent. Similarly, HIV-specific responses in treated
patients with and without detectable viremia during fol-
low-up were not significantly different. Numbers of Gag
SLYNTVATL-specific CD8
+ T-cells were inversely correlated
with the duration of HAART-induced undetectable plas-
ma viremia
Studies in animal and human models have shown
that antigen-specific CD8+ T-cells are critical for the con-
trols of HIV-1/SIV replication in vivo6. CD8+ T-cell re-
sponses specific for five HIV-1 proteins (Gag p17, Gag










Median age (years, range) 44.8 (33.9–62.2) 34.3 (22.7–67.1)
Sex ratio (males/females) 23/3 12/2
Median plasma viremia at the time of analysis (log10 copies/mL, range) Undetectable 4.7 (3.5–6.0)
Median CD4+ T-cell count at the time of analysis (cells/µL, range) 396.5 (117.0–965.0) 256.5 (31.0–525.0)
Median lowest CD4+ T-cell count (cells/µL, range) 49.0 (1.0–352.0) 200.5 (31.0–525.0)
Median lowest percentage of CD4+ T-cells (median, range) 7.0 (0.1–45.1) 22.0 (1.0–35.5)
Median duration of HAART-induced undetectable viremia (years, range) 5.2 (0.3–7.7) n.a.
Pre-treatment median plasma viremia (log10 copies/mL, range) 5.19 (4.07–6.92) n.a.
Pre-treatment median CD4+ T-cell count (cells/µL, range) 127.0 (1.0–407.0) n.a.
HAART – highly active antiretroviral therapy, n.a. – not applicable
TABLE 2
GAG SLYNTVATL-SPECIFIC CD8
+ T-CELLS IN HIV-PATIENTS RECEIVING LONG-TERM HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
(HAART) AND IN UNTREATED PATIENTS








Percentage of gag SLYNTVATL-specific CD8+ T-cells 0.10 (0.00–0.70) 0.10 (0.00–1.10) p=0.202
Number of gag SLYNTVATL-specific CD8+ T-cells per µl of blood 1 (0–6) 1 (0–9) p=0.579
Number of gag SLYNTVATL-specific CD8+ T-cells per 50,000 CD8+ T-cells 56 (2–344) 61 (10–573) p=0.533
* between group comparisons, Wilcoxon Two – sample test, p<0.05 was considered
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p24, reverse transcriptase, Env, Nef) in acute and chro-
nic infection/disease have been well characterized.
The majority of untreated chronically-infected pa-
tients who express the histocompatibility leukocyte anti-
gen (HLA)-A*0201 recognize the Gag p17 SLYNTVATL
(aa residues 77–85) epitope (SL9). Gag-specific T-cell re-
sponses can be detected in the majority of HIV-2-infected
individuals as well18.
The ability of HAART to suppress plasma viremia to
clinically undetectable levels has been well documented.
However, much less is known about the effect of long-
termHAART on the evolution of HIV-specific immunity.
According to some studies, a decline in plasma vire-
mia following HAART was accompanied by diminished
HIV-specific T-cell responses11–13. However, other studies
consistently showed the presence of HIV-specific T-cells
during antiretroviral therapy14–17. Appay et al showed
the maintenance of HIV-specific T-cell responses in pa-
tients who received HAART for up to 4 years16. Further-
more, Benito et al were able to demonstrate de novo ap-
pearance of HIV-specific CD8+ T-cells in patients on
successful HAART17.
Our study has shown the presence of HIV-specific
CD8+ T-cell responses in the majority of patients who
have been receiving HAART for long periods of time (me-
dian 5.5 years, maximum 8 years). Additionally, we did
not observe any difference in the amplitude of HIV-spe-
cific T-cell responses in treated patients with and without
detectable plasma viremia during follow-up.
The maintenance of HIV-specific T-cell immunity in
patients treated for several years is particularly impor-
tant in the context of viral evolution. Several studies
have shown that HIV-specific T-cells exert a selective
pressure on the virus that causes a dynamic viral evolu-
tion during chronic infection, which is an important issue
in immune evasion as well as for resistance to antiretro-
viral drugs7–10.
Additionally, the presence of a stable pool of HIV-spe-
cific T-cells in patients treated for long periods shown in
this study is relevant for further therapeutic strategies
that will combine antiviral and immunomodulatory ap-
proaches. It is reasonable to assume that long-term suc-
cessful anti-HIV treatment will be focused on the aug-
mentation or modulation of antigen-specific T-cell im-
munity. Similarities in the amplitude of Gag-specific
CD8+ T-cell responses in untreated and treated HIV-pa-
tients shown in this study support the relevance of this
concept. Additionally, further phenotypical and functio-
nal (intracellular cytokine expression) analysis of HIV-
specific T-cells detected in patients with long-term suc-
cessful HAART are needed to fully evaluate their contri-
bution to treatment-induced immune reconstitution5.
It has been difficult to establish a quantitative corre-
lation between the frequency of HIV-specific T-cells and
viremia in humans. For example, Buseyne et al (2002)
have shown a positive correlation between the frequen-
cies of ex-vivo activated HIV-specific CD8+ T-cells and
viremia in children19. Contrary to this finding, Benito et
al (2003) found a negative correlation between Gag- and
pol-specific CD8+ T-cell responses and viremia17. Accord-
ing to some studies, a negative correlation between the
frequency of HIV-specific CD8+ T-cells and plasma vire-
mia can be established only in patients with high CD4
T-cell counts (> 400/µL)20. Our study failed to show a sig-
nificant correlation between percentage and number
(per µL and per 50,000 CD8+ T-cells) in both treated and
untreated HIV-patients.
Oxenius et al (2002) showed an inverse correlation (in
a non-linear manner) between the frequency of HIV-spe-
cific T-cells and pre-treatment viremia in patients receiv-
ing HAART (median time on HAART 21 months)21. Ac-
cording to our results, there is no correlation between
the percentage and number of Gag-specific CD8+ T-cells
and pre-treatment viremia in patients on long-termHAART.
In conclusion, chronically-infected HIV-patients re-
ceiving HAART for long periods of time (up to 8 years)
maintained a stable subpopulation of Gag SLYNTVATL-spe-
cific CD8+ T-cells. This finding is relevant for the analy-
sis of treatment-induced immune reconstitution and,
possibly, for future therapeutic strategies in HIV-disease.
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PERZISTENTNA IMUNOREAKCIJA NA GAG PROTEIN HIV-a U BOLESNIKA
LIJE^ENIH HAART-OM
S A @ E T A K
U ovom smo istra`ivanju analizirali Gag-specifi~ne CD8+ T-limfocite u HIV-bolesnika lije~enih HAART-om kao i u
nelije~enih zara`enih osoba primjenom iTAg MHC tetramera klase 1 (HLA-A*0201) specifi~nih za SLYNTVATL. Gag
SLYNTVATL-specifi~ne CD8
+ T-limfocite dokazali smo u 18 od 26 lije~enih bolesnika (medjian 5,2 godine HAART-a) i u 10
od 14 nelije~enih pacijenata. Medijan postotka Gag SLYNTVATL-specifi~nih CD8
+ T-limfocita u lije~enih bolesnika bio je
0,10 (raspon 0,00–0,70%). Medijan broja Gag SLYNTVATL-specifi~nih CD8
+ T-limfocita na 50.000 CD8+ T-limfocita bio je
56,0 stanica (raspon 2,0–344,0 stanica) i nije bio zna~ajno razli~it u odnosu na nelije~ene zara`ene osobe (p=0,978).
Broj Gag SLYNTVATL-specifi~nih CD8
+ T-limfocita negativno je korelirao s du`inom perioda nemjerljive viremije u plazmi
(p=0,02, Rho= –0,430). U lije~enih HIV-bolesnika (do 7,7 godina HAART-a) postoji stabilna populacija Gag SLYNTVATL-
specifi~nih CD8+ T-limfocita. Rezultati ovog rada zna~ajni su za analizu lije~enjem-potaknute imunolo{ke rekonsti-
tucije te za razvoj novih strategija lije~enja u HIV-bolesti.
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